GlaxoSmithKline brings all-in-one therapy for HIV to China
Pharmaceutical giant GlaxoSmithKline (GSK) is rolling out its “blockbuster triple-therapy” HIV drug in Mainland China – and it’s debuting at a new, lower price-point, than in other parts of Asia. GSK is launching the treatment at a cost of $450 per month – lower than South Korea, Taiwan, and Hong Kong. Triumeq – the treatment’s name – is a combination of three drugs in a single pill. This means patients only need to remember to take one pill a day, rather than three, and it’s the first time such a treatment will be available in China.
GSK’s share price has risen by more than 10% so far this year
SOURCE: Yahoo Finance
Triumeq was approved by U.S. regulators (the Food and Drug Administration “FDA”) in 2014, and has since gained approval in more than 50 countries. Sales have soared – in 2016 alone, the therapy brought in $2.2 billion for GSK. It’s also been a market-share grabber, and given GSK the edge on competitor Gilead Sciences Inc., which was the clear market leader in HIV therapies for years beforehand.
Zhang Fujie from Beijing Ditan Hospital of Capital Medical University, was quoted in the GSK’s press release. He said that Triumeq “brings a more convenient treatment with high efficacy to Chinese people living with HIV. It poses less drug-drug interaction and has a high barrier to drug resistance.”
This is good news for the 746,000 HIV and AIDS sufferers living in China – especially if GSK can effectively negotiate with the Chinese government to get Triumeq included in the country’s free-treatment program.
GSK’s general manager for China pharmaceuticals and vaccines, Thomas Willemsen, made the following comment: “We are working closely with Chinese associations to undertake a series of initiatives, including professional training for HIV/AIDS care personnel, as well as disease prevention and education programmes, to enable Chinese people living with HIV (to) get better support and help”
Dominion holds GlaxoSmithKline in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.